KEYNOTE-183, 2018 trial summary

A randomised clinical trial investigating the effect of pembrolizumab + pomadoline + dexamethasone versus pomadoline + dexamethasone in refractory or relapsed and refractory Multiple Myeloma (rrMM)



Studied treatment pembrolizumab, Pomalidomide and low-dose Dexamethasone
Control treatment Pomalidomide and low-dose Dexamethasone

Patients refractory or relapsed and refractory Multiple Myeloma (rrMM)
Group sizes125 / 124

Blindness open-design Inclusion period
Follow-up duration 7.8 mo / 8.6 mo (median) Centers
Lost to FU geographical localisation
Primary endpoint Design Parallel groups

EndpointX1N1X0N0TE95% CI OS - 125 - 124 1,61[0,91; 2,85] PFS - 125 - 124 1,53[1,05; 2,22]0,22,01,0


press release

news record NCT02576977

Registering number NCT02576977 (see trial on
Code Name

Comment: Due to interim data presented to the data monitoring committees (DMC), the U.S. Food and Drug Administration (FDA) halted the trials and required that all patients in the two trials be discontinued